Abstract 386P
Background
Immune checkpoint inhibitors plus chemotherapy has demonstrated significant survival benefits for advanced non-small-cell lung cancer (NSCLC) patients without targetable mutations. Autologous cytokine-induced killer (CIK) cell therapy can restore the antitumor immunity to improve the patient outcomes. Therefore, a single-center, open-label, phase Ib trial was conducted to explore the efficacy and safety of autologous CIK cell therapy combined with sintilimab (anti-PD-1) plus chemotherapy as 1L treatment in advanced NSCLC patients (NCT03987867).
Methods
Systemic therapy naïve patients with stage IIIB-IV NSCLC would receive platinum-based doublet chemotherapy, sintilimab (200mg, d1), and intravenous autologous CIK cells (1010, d14) every 3 weeks until disease progression or unacceptable toxicity. The primary endpoints were safetyand the objective response rate (ORR) assessed per RECIST v1.1.Secondary endpoints were progression-free survival (PFS) and overall survival (OS).
Results
From May 2019 to Jun 2020, 16 pts aged 46-72 years (median age 62 years) were enrolled. The squamous/non-squamous ratio was 44%/56%. 14 (87.5%) were men, 15(93.7%) were ECOG PS=0-1, 3 (18.75%) had liver metastases, and 2 (12.5%) had brain metastases. Among 13 evaluable pts, the ORR and DCR were 84.6% and 100%, respectively. Among the 11 PR assessed by RECIST, CR was demonstrated in 3 (23.1%) by PET-CT. At the time of data cutoff, the median DOR was not reached (range 2.43m-NA), and the median PFS and OS were not mature (median follow-up time 5.65m, range 0.63-13.3).Adverse events (AEs) occurred in 15 (93.75%), including 4 Grade≥3 AEs events (25%). The most common AEs were nausea (12, 75%), anemia (11, 68.75%), and leukopenia (10, 62.5%).Immune-related AEs were cardiomyopathy (1, 6.25%) and pneumonia (3, 18.75%),1 pts had immune-related grade 5 pneumonia.
Conclusions
Autologous CIK cell therapy in combination with sintilimab plus chemotherapy were well tolerated and showed encouraging efficacy. Further studies are warranted to confirm these preliminary results.
Clinical trial identification
NCT03987867.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The National Key Technologies R&D Program of China grant Awards No. 2018YFC1313400 (to Jianchuan Xia).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
359P - The role of adjuvant targeted therapy for postoperative EGFR mutant non-small cell lung cancer: A network meta-analysis
Presenter: Guang Ling Jie
Session: e-Poster Display Session
360P - Number of lymph nodes examined was not an independent risk factor for the survival of patients with stage IA1-2 lung adenocarcinoma undergoing sublobar resection
Presenter: Zhenbin Qiu
Session: e-Poster Display Session
361P - Radiomic model predicting radiological response after thoracic stereotactic body radiotherapy regardless of tumor histology and staging
Presenter: Ben Man Fei Cheung
Session: e-Poster Display Session
362P - Integrative and comparative genomic analysis and immune microenvironment features of lung cancer patients with tuberculosis
Presenter: Xiaoling Xu
Session: e-Poster Display Session
363P - Genetic predisposition for pre-invasive lung adenocarcinoma manifesting as ground-glass nodules with family history of lung cancer
Presenter: Rui Fu
Session: e-Poster Display Session
364P - A deep learning model for the classification of lung cancer
Presenter: Gouji Toyokawa
Session: e-Poster Display Session
365P - Utilization of on-site pathology evaluation for lung cancer diagnosis in the Philippines’ National University Hospital
Presenter: Rich Ericson King
Session: e-Poster Display Session
367P - Detection of epidermal growth factor receptor mutations (EGFR-mut) from cell-free DNA in pleural effusion (PE-DNA) of patients with non-small cell lung cancer (NSCLC)
Presenter: Kirsty Lee
Session: e-Poster Display Session
368P - Real-world characteristics, treatment, and outcomes of stage III non-small cell lung cancer in Japan: SOLUTION study
Presenter: Haruyasu Murakami
Session: e-Poster Display Session
369P - The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer
Presenter: Long Jiang
Session: e-Poster Display Session